ArticleCardiovascular diabetology2022
The associations between changes in hepatic steatosis and heart failure and mortality: a nationwide cohort study.
Article in Cardiovascular diabetology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 33 citations in OpenAlex.
- Hepatic metabolic burden and all-cause mortality across glucose metabolism statuses in a cardiovascular-kidney-metabolic syndrome population: insights from the National Health and Nutrition Examination Survey (NHANES).Cardiovascular diabetology · 2026Article
- In-vivo liver proton density fat fraction quantification at 0.55 T: a pilot study with comparison against 3 T MRI.Magma (New York, N.Y.) · 2025Article
- Association between estimated glucose disposal rate and cardiovascular disease prevalence and mortality outcomes in metabolic dysfunction-associated steatotic liver disease: a comparative analysis of insulin resistance markers.Journal of global health · 2025Article
- Prognostic impact of systemic inflammation indicators on all-cause and CVD mortality in adults with MASLD.BMC gastroenterology · 2025Article
- Serum uric acid to high-density lipoprotein cholesterol ratio predicts all-cause mortality in adults with metabolic dysfunction associated steatotic liver disease.Scientific reports · 2025Article
- The dynamic patterns of metabolic-associated fatty liver disease and its severity and risk of cardiovascular disease.Hepatology international · 2025Article
- Hemoglobin glycation index and mortality risk in metabolic dysfunction-associated steatotic liver disease patients: a novel U-shaped association.Scientific reports · 2025Article
- Cardiometabolic dysfunction burden and mortality outcomes in metabolic dysfunction-associated steatotic liver disease.PloS one · 2025Article
- Clinical utility of the Fibrosis-4 index for predicting mortality in patients with heart failure with or without metabolic dysfunction-associated steatotic liver disease: a prospective cohort study.The Lancet regional health. Europe · 2025Article
- Association between body roundness index and risks of all-cause and cardiovascular mortality in adults with metabolic dysfunction-associated steatotic liver disease: NHANES 1999-2018.Frontiers in nutrition · 2025Article
- Life's essential 8 and mortality in US adults with metabolic dysfunction-associated steatotic liver disease.BMC public health · 2024Article
- A Systematic Review of Metabolic Syndrome: Key Correlated Pathologies and Non-Invasive Diagnostic Approaches.Journal of clinical medicine · 2024Review
- Prognostic effect of triglyceride glucose-related parameters on all-cause and cardiovascular mortality in the United States adults with metabolic dysfunction-associated steatotic liver disease.Cardiovascular diabetology · 2024Article
- Association between non-alcoholic fatty liver disease and subclinical left ventricular dysfunction in the general population.European heart journal open · 2023Article
- Association Between Ambroxol at the Usual Dose and the Risk of Parkinson's Disease in Chronic Lung Disease.Journal of clinical neurology (Seoul, Korea) · 2023Article
- Hepatic steatosis with significant fibrosis is associated with an increased 10-year estimated risk of cardiovascular disease in adults with type 1 diabetes mellitus.Cardiovascular diabetology · 2023Article
- Cardiac Structure and Function in Patients With Obesity and Non-alcoholic Fatty Liver Disease.Cureus · 2023Article
- Mechanisms Linking Metabolic-Associated Fatty Liver Disease (MAFLD) to Cardiovascular Disease.Current hypertension reports · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundNon-alcoholic fatty liver disease (NAFLD) is a well-known risk factor for cardiovascular (CV) disease (CVD) and mortality. However, whether the progression or regression of NAFLD can increase or decrease the risk of heart failure (HF) and mortality has not been fully evaluated. We investigated the association between changes in hepatic steatosis and the risks of incident HF (iHF), hospitalization for HF (hHF), and mortality including CV- or liver-related mortality.
methodsUsing a database from the National Health Insurance Service in Korea from January 2009 to December 2012, we analyzed 240,301 individuals who underwent health check-ups at least twice in two years. Hepatic steatosis was assessed using the fatty liver index (FLI), with an FLI ≥ 60 considered to indicate the presence of hepatic steatosis. According to FLI changes, participants were divided into four groups. Hazard ratios (HRs) and 95% confidence intervals (CIs) were estimated using multivariable Cox proportional hazards regression models.
resultsPersistent hepatic steatosis increased the risk of iHF, hHF, and mortality including CV- and liver-related mortality compared with the group that never had steatosis (all P < 0.05). Incident hepatic steatosis was associated with increased risk for iHF and mortality including CV- or liver-related mortality (all P < 0.05). Compared with persistent steatosis, regression of hepatic steatosis was associated with decreased risk for iHF, hHF, and liver-related mortality (iHF, HR [95% CI], 0.800 [0.691-0.925]; hHF, 0.645 [0.514-0.810]; liver-related mortality, 0.434 [0.223-0.846]).
conclusionsFLI changes were associated with increased or decreased risk of HF outcomes and mortality.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.